258 related articles for article (PubMed ID: 19494061)
1. Cephalosporin MIC distribution of extended-spectrum-{beta}-lactamase- and pAmpC-producing Escherichia coli and Klebsiella species.
Kohner PC; Robberts FJ; Cockerill FR; Patel R
J Clin Microbiol; 2009 Aug; 47(8):2419-25. PubMed ID: 19494061
[TBL] [Abstract][Full Text] [Related]
2. Plasmid-Mediated AmpC β-Lactamase and Underestimation of Extended-Spectrum β-Lactamase in Cefepime-Susceptible Elevated-Ceftazidime-MIC Enterobacteriaceae Isolates.
Nishimura F; Morinaga Y; Akamatsu N; Matsuda J; Kaku N; Takeda K; Uno N; Kosai K; Hasegawa H; Yanagihara K
Jpn J Infect Dis; 2018 Jul; 71(4):281-285. PubMed ID: 29709981
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the NCCLS extended-spectrum beta-lactamase confirmation methods for Escherichia coli with isolates collected during Project ICARE.
Tenover FC; Raney PM; Williams PP; Rasheed JK; Biddle JW; Oliver A; Fridkin SK; Jevitt L; McGowan JE;
J Clin Microbiol; 2003 Jul; 41(7):3142-6. PubMed ID: 12843054
[TBL] [Abstract][Full Text] [Related]
4. Can results obtained with commercially available MicroScan microdilution panels serve as an indicator of beta-lactamase production among escherichia coli and Klebsiella isolates with hidden resistance to expanded-spectrum cephalosporins and aztreonam?
Moland ES; Sanders CC; Thomson KS
J Clin Microbiol; 1998 Sep; 36(9):2575-9. PubMed ID: 9705395
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the Clinical and Laboratory Standards Institute phenotypic confirmatory test to detect the presence of extended-spectrum β-lactamases from 4005 Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae and Proteus mirabilis isolates.
Morrissey I; Bouchillon SK; Hackel M; Biedenbach DJ; Hawser S; Hoban D; Badal RE
J Med Microbiol; 2014 Apr; 63(Pt 4):556-561. PubMed ID: 24478449
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of MicroScan WalkAway and Vitek 2 for determination of the susceptibility of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates to cefepime, cefotaxime and ceftazidime.
Jang W; Park YJ; Park KG; Yu J
J Antimicrob Chemother; 2013 Oct; 68(10):2282-5. PubMed ID: 23671215
[TBL] [Abstract][Full Text] [Related]
7. Unreliable extended-spectrum beta-lactamase detection in the presence of plasmid-mediated AmpC in Escherichia coli clinical isolates.
Robberts FJ; Kohner PC; Patel R
J Clin Microbiol; 2009 Feb; 47(2):358-61. PubMed ID: 19109470
[TBL] [Abstract][Full Text] [Related]
8. Faecal colonization of E. coli and Klebsiella spp. producing extended-spectrum beta-lactamases and plasmid-mediated AmpC in Mozambican university students.
Chirindze LM; Zimba TF; Sekyere JO; Govinden U; Chenia HY; Sundsfjord A; Essack SY; Simonsen GS
BMC Infect Dis; 2018 May; 18(1):244. PubMed ID: 29843632
[TBL] [Abstract][Full Text] [Related]
9. Susceptibility patterns to extended-spectrum cephalosporins among Enterobacteriaceae harbouring extended-spectrum β-lactamases using the updated Clinical and Laboratory Standards Institute interpretive criteria.
Kristo I; Pitiriga V; Poulou A; Zarkotou O; Kimouli M; Pournaras S; Tsakris A
Int J Antimicrob Agents; 2013 Apr; 41(4):383-7. PubMed ID: 23375981
[TBL] [Abstract][Full Text] [Related]
10. Relationship between the distribution of cefepime minimum inhibitory concentrations and detection of extended-spectrum β-lactamase production among clinically important Enterobacteriaceae isolates obtained from patients in intensive care units in Taiwan: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2007.
Jean SS; Lee WS; Bai KJ; Lam C; Hsu CW; Yu KW; Liao CH; Chang FY; Ko WC; Wu JJ; Chen YH; Chen YS; Liu JW; Lu MC; Liu CY; Chen RJ; Hsueh PR
J Microbiol Immunol Infect; 2015 Feb; 48(1):85-91. PubMed ID: 23973410
[TBL] [Abstract][Full Text] [Related]
11. Susceptibility of extended-spectrum-beta-lactamase-producing Enterobacteriaceae according to the new CLSI breakpoints.
Wang P; Hu F; Xiong Z; Ye X; Zhu D; Wang YF; Wang M
J Clin Microbiol; 2011 Sep; 49(9):3127-31. PubMed ID: 21752977
[TBL] [Abstract][Full Text] [Related]
12. Use of the cefepime-clavulanate ESBL Etest for detection of extended-spectrum beta-lactamases in AmpC co-producing bacteria.
Mohanty S; Gaind R; Ranjan R; Deb M
J Infect Dev Ctries; 2009 Nov; 4(1):24-9. PubMed ID: 20130375
[TBL] [Abstract][Full Text] [Related]
13. The molecular characteristics of cefepime-susceptible Escherichia coli and Klebsiella spp. isolates with a positive β-lactamase screening test result but negative confirmation.
Hu F; Wu W; Ye X; Xu X; Zhu D
Eur J Clin Microbiol Infect Dis; 2010 Oct; 29(10):1297-9. PubMed ID: 20549530
[TBL] [Abstract][Full Text] [Related]
14. Comparison of screening methods for detection of extended-spectrum beta-lactamases and their prevalence among blood isolates of Escherichia coli and Klebsiella spp. in a Belgian teaching hospital.
Vercauteren E; Descheemaeker P; Ieven M; Sanders CC; Goossens H
J Clin Microbiol; 1997 Sep; 35(9):2191-7. PubMed ID: 9276386
[TBL] [Abstract][Full Text] [Related]
15. Laboratory identification, risk factors, and clinical outcomes of patients with bacteremia due to Escherichia coli and Klebsiella pneumoniae producing extended-spectrum and AmpC type β-lactamases.
Tsui K; Wong SS; Lin LC; Tsai CR; Chen LC; Huang CH
J Microbiol Immunol Infect; 2012 Jun; 45(3):193-9. PubMed ID: 22580086
[TBL] [Abstract][Full Text] [Related]
16. Identification of plasmid-mediated AmpC beta-lactamases in Escherichia coli, Klebsiella spp., and proteus species can potentially improve reporting of cephalosporin susceptibility testing results.
Tenover FC; Emery SL; Spiegel CA; Bradford PA; Eells S; Endimiani A; Bonomo RA; McGowan JE
J Clin Microbiol; 2009 Feb; 47(2):294-9. PubMed ID: 19036936
[TBL] [Abstract][Full Text] [Related]
17. Cefotaxime for the detection of extended-spectrum β-lactamase or plasmid-mediated AmpC β-lactamase and clinical characteristics of cefotaxime-non-susceptible Escherichia coli and Klebsiella pneumoniae bacteraemia.
Matsumura Y; Yamamoto M; Matsushima A; Nagao M; Ito Y; Takakura S; Ichiyama S
Eur J Clin Microbiol Infect Dis; 2012 Aug; 31(8):1931-9. PubMed ID: 22210267
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of flomoxef and comparators against Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis producing extended-spectrum β-lactamases in China.
Yang Q; Zhang H; Cheng J; Xu Z; Xu Y; Cao B; Kong H; Ni Y; Yu Y; Sun Z; Hu B; Huang W; Wang Y; Wu A; Feng X; Liao K; Shen D; Hu Z; Chu Y; Lu J; Su J; Gui B; Duan Q; Zhang S; Shao H
Int J Antimicrob Agents; 2015 May; 45(5):485-90. PubMed ID: 25600890
[TBL] [Abstract][Full Text] [Related]
19. In vitro activities and detection performances of cefmetazole and flomoxef for extended-spectrum β-lactamase and plasmid-mediated AmpC β-lactamase-producing Enterobacteriaceae.
Matsumura Y; Yamamoto M; Nagao M; Tanaka M; Takakura S; Ichiyama S
Diagn Microbiol Infect Dis; 2016 Apr; 84(4):322-7. PubMed ID: 26782634
[TBL] [Abstract][Full Text] [Related]
20. A nationwide study of mechanisms conferring reduced susceptibility to extended-spectrum cephalosporins in clinical Escherichia coli and Klebsiella spp. isolates.
Tofteland S; Dahl KH; Aasnæs B; Sundsfjord A; Naseer U
Scand J Infect Dis; 2012 Dec; 44(12):927-33. PubMed ID: 22991975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
